Research programme: COVID-19 vaccines - Gritstone bio
Alternative Names: CORAL programme - Gritstone BioLatest Information Update: 08 Mar 2024
Price :
$50 *
At a glance
- Originator Gritstone bio
- Class COVID-19 vaccines; RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 12 Feb 2024 Gritstone bio plans a phase IIb CORAL-BARDA trial in COVID-2019 infections (Prevention) in the fall of 2024
- 19 Dec 2022 Gritstone bio has patent protection for antigen-encoding samRNA vectors and its applicability across candidates in oncology and infectious disease in USA
- 31 Aug 2021 Gritstone bio has patent protection for EDGETM platform